Fate Therapeutics (FATE) Enterprise Value (2013 - 2026)

Fate Therapeutics (FATE) has 15 years of Enterprise Value data on file, last reported at -$174.8 million in Q1 2026.

• Quarterly Enterprise Value rose 27.29% year-over-year to -$174.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$174.8 million (up 27.29% YoY) and the FY2025 annual result came in at -$203.7 million, up 27.02% from the prior year.
• Enterprise Value advanced to -$174.8 million in Q1 2026, from -$203.7 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$174.8 million in Q1 2026 to a low of -$573.8 million in Q1 2022.
• A 5-year average of -$344.5 million and a median of -$315.2 million in 2023 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value gained 6.2% — and 2025, when it surged 37.31%.
• Tracing FATE's Enterprise Value over 5 years: stood at -$436.2 million in 2022, then increased by 27.75% to -$315.2 million in 2023, then rose by 11.46% to -$279.1 million in 2024, then increased by 27.02% to -$203.7 million in 2025, then climbed by 14.16% to -$174.8 million in 2026.
• The last three Enterprise Value figures came in at -$174.8 million (Q1 2026), -$203.7 million (Q4 2025), and -$215.4 million (Q3 2025), per Business Quant data.